Superior Outcomes With Continuing Tenofovir Versus Switching to Zidovudine in Second-Line Antiretroviral Therapy in Haiti. (23rd November 2021)

• Record Type: Journal Article
• Authors: Pierre, Samuel; Bocharova, Iryna; Nguyen, Catherine; Homeus, Fabienne; Julmiste, Gaetane; Macius, Youry; Rouzier, Vanessa; Severe, Patrice; Marcelle Deschamps, Marie; Moise, Colette Guiteau; Bellot, Clovy; Wu, Johnny; Rivera, Vanessa R; Sun, Rochelle; Pape, Jean W; Liautaud, Bernard; Koenig, Serena P
• Is Part Of: Open forum infectious diseases. Volume 8:Number 12(2021)
• Publication Date: 2021-11-23
• Subjects: genotypic resistance -- HIV -- second-line therapy -- tenofovir disoproxil fumarate -- zidovudine; Communicable diseases -- Periodicals; Medical microbiology -- Periodicals; Infection -- Periodicals; 616.9
• DOI: 10.1093/ofid/ofab559
• Languages: English
• ISSNs: 2328-8957

Abstract

Abstract: We compared viral suppression rates between patients who continued tenofovir disoproxil fumarate (TDF)/lamivudine (3TC) vs switched to zidovudine (ZDV)/3TC in combination with a boosted protease inhibitor after failure of first-line efavirenz/TDF/3TC. We found higher rates of viral suppression with continued TDF/3TC compared with switching to ZDV/3TC.